NCT07030764 Comparison of Arthrogenic Muscle Inhibition (AMI) After ACL Reconstruction in Patients With Conventional Rehabilitation or Conventional Rehabilitation Combined With Digital Therapy
| NCT ID | NCT07030764 |
| Status | Recruiting |
| Phase | — |
| Sponsor | GCS Ramsay Santé pour l'Enseignement et la Recherche |
| Condition | ACL - Anterior Cruciate Ligament Rupture |
| Study Type | INTERVENTIONAL |
| Enrollment | 448 participants |
| Start Date | 2025-07-25 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 448 participants in total. It began in 2025-07-25 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Traumatic injury to the knee joint, such as rupture of the anterior cruciate ligament (ACL), can compromise the voluntary activation capacity of the quadriceps despite the anatomical integrity of the nerve and muscle structures responsible for contraction. This phenomenon is commonly known as 'arthrogenic muscle inhibition' (AMI). AMI is a major limiting factor in recovery and rehabilitation after ACL rupture, and a potential cause of functional disability if left undiagnosed and untreated. Traditional rehabilitation protocols for ACL reconstruction do not adequately address the underlying neuromuscular deficits caused by AMI, leading to sub-optimal recovery and prolonged rehabilitation. Furthermore, patient adherence to these protocols, outside of supervised settings, is variable and often poor, which can further delay recovery Recent advances in digital health technologies offer new ways of improving rehabilitation outcomes. Numerous studies highlight the effectiveness of digital therapies in the form of mobile applications in improving patient engagement and compliance with rehabilitation protocols. In addition, evidence suggests that the integration of these technologies enables faster recovery of muscle function, reduces pain levels, may reduce complications such as Cyclops syndrome and improves overall patient satisfaction with rehabilitation. Healing has developed a digital therapy called DOCT'UP® which, in addition to physiotherapy sessions, offers support programmes for patients following ACL reconstruction. These programmes include self-education exercises to be carried out at home, some of which specifically target the AMI phenomenon. DOCT'UP® digital therapy has already been used in rehabilitation after ACL reconstruction, with results at 3 weeks on quadriceps activation and post-operative pain, as well as at 1 year on Cyclops syndrome. Given the limitations of current rehabilitation practices in the context of AMI and the potential of the DOCT'UP® application, there is a clear need to scientifically assess whether the DOCT'UP® application can effectively improve the results of rehabilitation on AMI after ACL reconstruction. This is why the sponsor wishes to set up this Clinical Investigation.
Eligibility Criteria
Inclusion Criteria: * Patient, male or female, aged ≥ 18 years * Patient with a scheduled primary ACL reconstruction * Patient with a smartphone and able to use a mobile application on a smartphone * Patient affiliated to or benefiting from a social security scheme * French-speaking patient who has signed an informed consent form Exclusion Criteria: * Patients with residual AMI * Patient with previous ipsi or contralateral knee surgery * Patient with a multi-ligament injury * Patient with contraindications to physical exercise: severe cardiovascular disease or uncontrolled metabolic disease * Patients with cognitive problems * Patient without internet access * Patient taking part in another study * Pregnant or breast-feeding women * Protected patient: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07030764 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying ACL - Anterior Cruciate Ligament Rupture. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07030764 currently recruiting?
Yes, NCT07030764 is actively recruiting participants. Contact the research team at benjamin.freychet@gmail.com for enrollment information.
Where is the NCT07030764 trial being conducted?
This trial is being conducted at Lyon, France.
Who is sponsoring the NCT07030764 clinical trial?
NCT07030764 is sponsored by GCS Ramsay Santé pour l'Enseignement et la Recherche. The trial plans to enroll 448 participants.